AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39043009 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose-expansion cohorts
Number of subjects: 71
Study 39043009 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 71
Study 39043146 — intervention group
Group type: EXPERIMENTAL
Intervention: FYTF-919 (100 mL per day, oral)
Number of subjects: 1504
Study 39043146 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1504
Study 39043201 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Scale (VS) measurement
Number of subjects: 120
Study 39043201 — intervention group
Group type: COMPARATOR
Intervention: Visual measurement
Number of subjects: 120
Study 39043201 — intervention group
Group type: COMPARATOR
Intervention: Snare measurement
Number of subjects: 120
Study 39043201 — intervention group
Group type: COMPARATOR
Intervention: Visual and Snare measurements
Number of subjects: 120
Study 39043348 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA, 81 mg/day) during sleep restriction
Number of subjects: 46
Study 39043348 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (ASA, 81 mg/day) during recovery sleep
Number of subjects: 46
Study 39043348 — intervention group
Group type: COMPARATOR
Intervention: Placebo during sleep restriction
Number of subjects: 46
Study 39043397 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Number of subjects: 12137
Study 39043397 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 12137
Study 39043416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraosseous access
Number of subjects: 1732
Study 39043416 — intervention group
Group type: COMPARATOR
Intervention: Intravenous access
Number of subjects: 1732
Study 39043465 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PD psychosis (PDP)
Number of subjects: 676
Study 39043465 — intervention group
Group type: COMPARATOR
Intervention: Patients with PD without psychosis (PDnP)
Number of subjects: 676
Study 39043465 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 676
Study 39043513 — intervention group
Group type: EXPERIMENTAL
Intervention: StrataGraft treatment
Number of subjects: 52
Study 39043586 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents living with obesity (ALwO)
Number of subjects: 416
Study 39043586 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers of ALwO
Number of subjects: 416
Study 39043586 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals (HCPs)
Number of subjects: 416
Study 39043586 — intervention group
Group type: EXPERIMENTAL
Intervention: ALwO discussing weight with HCPs
Number of subjects: 416
Study 39043586 — intervention group
Group type: EXPERIMENTAL
Intervention: ALwO and caregivers seeking information
Number of subjects: 416
Study 39043586 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort level of ALwO and caregivers
Number of subjects: 416
Study 39043588 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based peer support programme with standard care
Number of subjects: 442
Study 39043588 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 442
Study 39043593 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy plus health education (intervention group, n=20)
Number of subjects: 40
Study 39043593 — intervention group
Group type: COMPARATOR
Intervention: Health education (control group, n=20)
Number of subjects: 40
Study 39043650 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 min daily HVBR (fast breathing with long breath holds) for 3 weeks
Number of subjects: 200
Study 39043650 — intervention group
Group type: COMPARATOR
Intervention: Placebo HVBR (15 breaths/min with short breath holds) for 3 weeks
Number of subjects: 200
Study 39043682 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PEX)
Number of subjects: 22
Study 39043682 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (Control)
Number of subjects: 22
Study 39043871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) maintenance after ASCT
Number of subjects: 245
Study 39043871 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ hematopoietic stem cells (PBSC) harvesting and reinfusion
Number of subjects: 245
Study 39043915 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk supplementation (390 ml daily)
Number of subjects: 315
Study 39043915 — intervention group
Group type: COMPARATOR
Intervention: Dairy supplementation (meta-analysis)
Number of subjects: 315
Study 39043982 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical resection with fMRI evaluation preoperatively and regular follow-up postoperatively.
Number of subjects: 346
Study 39043982 — intervention group
Group type: EXPERIMENTAL
Intervention: LED performance for predicting unfavorable outcomes in compact BAVMs.
Number of subjects: 346
Study 39043982 — intervention group
Group type: EXPERIMENTAL
Intervention: LED performance for predicting unfavorable outcomes in diffuse BAVMs.
Number of subjects: 346
Study 39044019 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher severity of common mental disorders (CMDs)
Number of subjects: 2486
Study 39044019 — intervention group
Group type: EXPERIMENTAL
Intervention: Being unmarried (for women)
Number of subjects: 2486
Study 39044019 — intervention group
Group type: EXPERIMENTAL
Intervention: No formal education (for men)
Number of subjects: 2486
Study 39044019 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 60 years
Number of subjects: 2486
Study 39044019 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate and severe depression
Number of subjects: 2486
Study 39044019 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate anxiety
Number of subjects: 2486
Study 39044224 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Literacy and Nutrition (FLAN) curriculum
Number of subjects: 39
Study 39044224 — intervention group
Group type: COMPARATOR
Intervention: Nutrition information-only control
Number of subjects: 39
Study 39044295 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 hours of therapeutic cooling
Number of subjects: 1800
Study 39044295 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of therapeutic cooling
Number of subjects: 1800
Study 39044295 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hours of therapeutic cooling
Number of subjects: 1800
Study 39044295 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter and longer duration arms (between 12 and 48 hours)
Number of subjects: 1800
Study 39044295 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 1800
Study 39044295 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (not explicitly mentioned as a control)
Number of subjects: 1800
Study 39044381 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (10 mg/kg once) with fluconazole
Number of subjects: 168
Study 39044381 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole alone
Number of subjects: 168
Study 39044381 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B with fluconazole
Number of subjects: 168
Study 39044659 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged PCI at earlier timing (5-7 weeks)
Number of subjects: 150
Study 39044659 — intervention group
Group type: COMPARATOR
Intervention: Staged PCI at later timing (12-14 weeks)
Number of subjects: 150
Study 39044792 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time guiding using deep learning during echocardiography
Number of subjects: 0
Study 39044797 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept
Number of subjects: 14
Study 39044797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 39044861 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection
Number of subjects: 300
Study 39044861 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 severe disease
Number of subjects: 300
Study 39044861 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 300
Study 39044861 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine adverse effects after dose one
Number of subjects: 300
Study 39044861 — intervention group
Group type: EXPERIMENTAL
Intervention: CD flares after SARS-CoV-2 infection
Number of subjects: 300
Study 39044861 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-spike titer after vaccination
Number of subjects: 300
Study 39045032 — intervention group
Group type: EXPERIMENTAL
Intervention: EDucation on load management plus eXercise (EDX) delivered in 6 sessions over 8 weeks
Number of subjects: 64
Study 39045032 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 64
Study 39045079 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time guidance by deep learning (DL) for experienced sonographers
Number of subjects: 0
Study 39045079 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 39045200 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial cardiac magnetic resonance (CMR) imaging
Number of subjects: 18
Study 39045200 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP) assay
Number of subjects: 18
Study 39045229 — intervention group
Group type: EXPERIMENTAL
Intervention: F3-App (interactive educational software)
Number of subjects: 0
Study 39045392 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized, nature-based and other outdoor VR content for patient-caregiver dyads
Number of subjects: 0
Study 39045484 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including training sessions for health workers, patient education materials, storytelling intervention, home BP self-monitoring, and expanded community health worker services.
Number of subjects: 671
Study 39045484 — intervention group
Group type: COMPARATOR
Intervention: Comparison group received training sessions about hypertension prevention and management for health workers and patient education materials.
Number of subjects: 671
Study 39045484 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 671
Study 39045544 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab (240 mg) every 3 weeks plus nab-paclitaxel weekly for 12 weeks after four cycles of epirubicin-cyclophosphamide every 2 weeks
Number of subjects: 70
Study 39045554 — intervention group
Group type: COMPARATOR
Intervention: Sham intermittent theta burst stimulation (iTBS)
Number of subjects: 1
Study 39045554 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS)
Number of subjects: 1
Study 39045754 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)
Number of subjects: 100
Study 39045758 — intervention group
Group type: EXPERIMENTAL
Intervention: High EVOO diet (4 tablespoons/day)
Number of subjects: 40
Study 39045758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low EVOO diet (<1 teaspoon/day)
Number of subjects: 40
Study 39045758 — intervention group
Group type: EXPERIMENTAL
Intervention: Low EVOO diet followed by high EVOO diet
Number of subjects: 40
Study 39045795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for PTSD
Number of subjects: 0
Study 39045819 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P (SSTP) intervention
Number of subjects: 0
Study 39045819 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study 39046150 — intervention group
Group type: EXPERIMENTAL
Intervention: VISITECT CD4 Advanced Disease test
Number of subjects: 1604
Study 39046157 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lenacapavir every 26 weeks
Number of subjects: 5338
Study 39046157 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral emtricitabine-tenofovir alafenamide (F/TAF)
Number of subjects: 5338
Study 39046157 — intervention group
Group type: COMPARATOR
Intervention: Daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF; active control)
Number of subjects: 5338
Study 39046314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hip injection with prior subcutaneous LA (2 mL of lidocaine 1%)
Number of subjects: 41
Study 39046314 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular hip injection without prior subcutaneous LA
Number of subjects: 41
Study 39046314 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular hip injection with prior subcutaneous LA
Number of subjects: 41
Study 39046333 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 39046333 — intervention group
Group type: COMPARATOR
Intervention: Concomitant inhibitors or inducers of cytochrome P450 3A4 and/or P-glycoprotein
Number of subjects: 0
Study 39046616 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 618
Study 39046616 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 618
Study 39046616 — intervention group
Group type: EXPERIMENTAL
Intervention: FACT-GP5
Number of subjects: 618
Study 39046635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of natalizumab
Number of subjects: 153
Study 39046635 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of natalizumab
Number of subjects: 153
Study 39046647 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanjie Analgesic Capsule (SAC) 1.6 g 3 times per day for 3 menstrual cycles
Number of subjects: 323
Study 39046647 — intervention group
Group type: COMPARATOR
Intervention: Placebo 1.6 g 3 times per day for 3 menstrual cycles
Number of subjects: 323
Study 39046695 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting muscarinic antagonist (LAMA)
Number of subjects: 414
Study 39046695 — intervention group
Group type: EXPERIMENTAL
Intervention: LAMA + long-acting β agonist
Number of subjects: 414
Study 39046695 — intervention group
Group type: EXPERIMENTAL
Intervention: Other inhaler treatments
Number of subjects: 414
Study 39046695 — intervention group
Group type: COMPARATOR
Intervention: Inhaler treatment (general)
Number of subjects: 414
Study 39046727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin for 24 weeks
Number of subjects: 37
Study 39046727 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 37
Study 39046741 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group (pharmacist-led OAC prescription)
Number of subjects: 80
Study 39046741 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intervention, usual care)
Number of subjects: 80
Study 39046767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (10 mg twice daily for ages ≥12 to <18 years; 5 mg twice daily for ages ≥6 to <12 years; 4 mg/m2 twice daily for ages ≥2 to <6 years)
Number of subjects: 45
Study 39046783 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC/SIR/TAC
Number of subjects: 28
Study 39046800 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39046973 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus fermentum TSF331, Lactobacillus reuteri TSR332, and Lactobacillus plantarum TSP05
Number of subjects: 82
Study 39047125 — intervention group
Group type: EXPERIMENTAL
Intervention: Microserrated forceps
Number of subjects: 90
Study 39047125 — intervention group
Group type: COMPARATOR
Intervention: Conventional forceps
Number of subjects: 90
Study 39047180 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartfulness self-care program (4-week web-based program)
Number of subjects: 203
Study 39047180 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 203
Study 39047219 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended letrozole therapy (ELT)
Number of subjects: 1866
Study 39047219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1866
Study 39047238 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited sampling strategies (LSSs) for mycophenolic acid (MPA)
Number of subjects: 84
Study 39047238 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited sampling strategies (LSSs) for mycophenolic acid (MPA) in high EHR group
Number of subjects: 84
Study 39047240 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 488
Study 39047240 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy-only
Number of subjects: 488
Study 39047258 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP prevalence at 3 months
Number of subjects: 159
Study 39047258 — intervention group
Group type: EXPERIMENTAL
Intervention: CPSP prevalence at 24 months
Number of subjects: 159
Study 39047258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity as a presurgical predictor for CPSP
Number of subjects: 159
Study 39047258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing as a presurgical predictor for CPSP
Number of subjects: 159
Study 39047258 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain anxiety as a presurgical predictor for CPSP
Number of subjects: 159
Study 39047258 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based trajectory modeling for postsurgical pain
Number of subjects: 159
Study 39047288 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-assessed VAT index
Number of subjects: 3730
Study 39047288 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-assessed SAT
Number of subjects: 3730
Study 39047288 — intervention group
Group type: EXPERIMENTAL
Intervention: VAT/SAT ratio
Number of subjects: 3730
Study 39047288 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference values for SAT and VAT
Number of subjects: 3730
Study 39047811 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM intervention
Number of subjects: 0
Study 39047811 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 39047868 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (20 g/day for 7 days)
Number of subjects: 3
Study 39047868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 39047868 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study 39047868 — intervention group
Group type: COMPARATOR
Intervention: Creatine, Placebo, Control
Number of subjects: 3
Study 39048019 — intervention group
Group type: EXPERIMENTAL
Intervention: Womed Leaf film inserted
Number of subjects: 160
Study 39048019 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Womed Leaf film)
Number of subjects: 160
Study 39048132 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a surgical face mask in public spaces for 14 days
Number of subjects: 4647
Study 39048132 — intervention group
Group type: COMPARATOR
Intervention: Not wearing a surgical face mask in public places
Number of subjects: 4647
Study 39048547 — intervention group
Group type: EXPERIMENTAL
Intervention: SCTV01E
Number of subjects: 9223
Study 39048547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9223
Study 39048549 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 43
Study 39048549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 39048608 — intervention group
Group type: EXPERIMENTAL
Intervention: Clesacostat (PF-05221304), an acetyl coA carboxylase inhibitor (ACCi), 25 mg dosage.
Number of subjects: 231
Study 39048608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 39048638 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care plus durvalumab and oleclumab (experimental arm)
Number of subjects: 52
Study 39048638 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (control arm)
Number of subjects: 52
Study 39048701 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Manual Therapy (ETManual therapy)
Number of subjects: 55
Study 39048701 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone (ET)
Number of subjects: 55
Study 39048701 — intervention group
Group type: COMPARATOR
Intervention: Exercise + Kinesio Tape (ETkinesiotape)
Number of subjects: 55
Study 39048748 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel polyp retrieval bag
Number of subjects: 204
Study 39048748 — intervention group
Group type: COMPARATOR
Intervention: Control group (polyp trap through instrument channel)
Number of subjects: 204
Study 39048932 — intervention group
Group type: EXPERIMENTAL
Intervention: POINCARE-2 strategy (daily weighing and administration of treatments)
Number of subjects: 0
Study 39048932 — intervention group
Group type: COMPARATOR
Intervention: Control period (standard care without POINCARE-2 strategy)
Number of subjects: 0
Study 39048932 — intervention group
Group type: EXPERIMENTAL
Intervention: POINCARE-2 strategy
Number of subjects: 0
Study 39048933 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise programme in primary care (aerobic and strengthening exercises, twice a week for 12 weeks, daily walks)
Number of subjects: 90
Study 39048933 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise programme in primary care
Number of subjects: 90
Study 39048933 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised home-based exercise (daily walks and sit-to-stand exercise)
Number of subjects: 90
Study 39048985 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary paxillin levels in patients with OSCC
Number of subjects: 45
Study 39048985 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary paxillin levels in patients with OPMDs
Number of subjects: 45
Study 39048985 — intervention group
Group type: COMPARATOR
Intervention: ROC analysis between OPMDs and OSCC
Number of subjects: 45
Study 39049019 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential 4-channel neuromuscular electrical stimulation (NMES)
Number of subjects: 0
Study 39049044 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-self management training (DSMT)
Number of subjects: 0
Study 39049044 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote glucose monitoring (RGM)
Number of subjects: 0
Study 39049044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored support from a community health worker (CHW)
Number of subjects: 0
Study 39049044 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching study arms (for nonresponders)
Number of subjects: 0